Benzinga | Jul 21, 2021 08:07AM EDT

Merus Highlights Publication In Nature Communications On MCLA-145's Novel Mechanism Of Action Promoting Tumor Immunity And Context Dependent T-Cell Costimulation

Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics(r) and Triclonics(r)), today announced the novel mechanism of action (MOA) of MCLA-145, the Company's clinical stage Biclonics(r) T-cell agonist. MCLA-145 binds with high affinity and specificity to PD-L1 and CD137. The unique immunostimulatory mechanism of action of MCLA-145 was published in Nature Communications on June 21, 2021, titled "A human CD137?PD-L1 bispecific antibody promotes anti-tumor immunity via context dependent T cell costimulation and checkpoint blockade."